MOSCOW: Russia’s Sputnik-V vaccine and its one-shot version Sputnik Light booster demonstrates high virus-neutralising activity (VNA) against the highly-contagious Omicron variant of COVID-19, providing a strong defence against severe disease and hospitalisation, according to a study.
The Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), an investor in Sputnik V and Sputnik Light vaccines, in an article titled “Sputnik Light booster after Sputnik V vaccination induces robust neutralising antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant” said that the vaccine is expected to provide a strong defence against severe disease and hospitalisation.
The study was conducted using sera with a long period after vaccination (more than 6 months after vaccination) as an indicator of Sputnik V’s long-lasting protection, Sputnik-V said in a statement on Wednesday.
